SearcharxivSearch

arXiv subjects

Josh Loecker

Publications and source records attributed to Josh Loecker.

2 recordsLinked to original sources

MechAInistic: An LLM-guided Multi-Agent System for Reasoning over Genome-Scale Constraint-Based Metabolic Models

Constraint-based metabolic modeling is a powerful way to study the mechanistic basis of cellular states and disease, but its effective use demands substantial computational expertise and careful coordination of multi-step analyses. We developed MechAInistic to lower this barrier and enable researchers to ask complex biological questions in natural language. Harnessing large language models, MechAInistic is a multi-agent system organized around an Architect-Reviewer pattern that transforms a natural-language question into an executable, model-grounded workflow and generates a structured report. The system supports a variety of tasks, including pathway comparison, perturbation analysis, drug-target exploration, and literature-grounded interpretation across paired metabolic model states. We developed and evaluated MechAInistic using two paired immune-cell metabolic-model use cases for therapeutic hypothesis generation. For Naive B cells from rheumatoid arthritis (RA) paired with healthy controls, MechAInistic identified mitochondrial metabolic rewiring and nominated Devimistat/CPI-613 as an investigational OGDH-centered hypothesis. In a paired CD4+ Th17 cell study from multiple sclerosis (MS) and healthy controls, the same workflow identified NADP-dependent isocitrate dehydrogenase as the optimal single target and proposed ivosidenib as an FDA-approved repurposing candidate. Together, these results show that MechAInistic converts natural-language biological questions into executable, model-grounded workflows for traceable therapeutic hypothesis generation.

q-bio.QM

COMO: A Pipeline for Multi-Omics Data Integration in Metabolic Modeling and Drug Discovery

Identifying potential drug targets using metabolic modeling requires integrating multiple modeling methods and heterogenous biological datasets, which can be challenging without sophisticated tools. We developed COMO, a user-friendly pipeline that integrates multi-omics data processing, context-specific metabolic model development, simulations, drug databases, and disease data to aid drug discovery. COMO can be installed as a Docker image and includes intuitive instructions within a Jupyter Lab environment. It provides a comprehensive solution for multi-omics integration of bulk and single-cell RNA-seq, microarrays, and proteomics to develop context-specific metabolic models. Using public databases, open-source solutions for model construction, and a streamlined approach for predicting repurposable drugs, COMO empowers researchers to investigate low-cost alternatives and novel disease treatments. As a case study, we used the pipeline to construct metabolic models of B cells, which simulate and analyze them to predict 25 and 23 metabolic drug targets for rheumatoid arthritis and systemic lupus erythematosus, respectively. COMO can be used to construct models for any cell or tissue type and identify drugs for any human disease. The pipeline has the potential to improve the health of the global community cost-effectively by providing high-confidence targets to pursue in preclinical and clinical studies.

q-bio.MN